Portfolio News
Sofinnova Capital
RefleXion expands access to SCINTIX therapy with first freestanding cancer center
HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, a theranostic oncology company, today announced the scheduled installation of its RefleXion® X1 platform with SCINTIX® biology-guided radiotherapy at Beverly Hills Cancer Center (BHCC), the first freestanding cancer center (FSCC) that has installed the RefleXion X1.
“At BHCC, we are committed to advancing cancer care by integrating the latest innovations, ensuring our patients receive the highest quality, cutting-edge treatments,” said Arash (Ari) Gabayan, M.D., Chief of Radiation Oncology and Imaging at Beverly Hills Cancer Center. “We are excited to be amongst the first centers in the world to offer our patients this breakthrough technology, which uses the inherent biology of the patient’s tumor to precisely direct the radiation beam to its tumor target.
“This is a totally new and exciting concept in radiation treatment delivery, and we believe that using the tumor’s own biology will transform how patients are treated,” Dr. Gabayan continued.
The RefleXion X1 machine with SCINTIX therapy is designed to use biology guidance to precisely treat one or more targets within the same treatment session. Early clinical cases have demonstrated that when the tumor moves, SCINTIX therapy autonomously shifts the radiation dose to follow the tumor, thereby safely delivering radiation to the tumor target while sparing radiation exposure to healthy tissue.
“We are thrilled to count BHCC and its world-class cancer physicians among our early customers and as our first freestanding cancer center,” said Todd Powell, president and CEO of RefleXion. “Their commitment to providing access to cutting-edge cancer treatments like SCINTIX therapy is invaluable.”
Beginning in 2025, the Centers for Medicare and Medicaid Services (CMS) will expand reimbursement for SCINTIX therapy, introducing new billing codes for FSCCs and professional reimbursement for physicians in both FSCCs and hospital outpatient departments.
“We are encouraged that CMS has expanded reimbursement for freestanding cancer centers like BHCC as this supports clinicians who advance clinical adoption of new technologies and treatments,” continued Powell.
BHCC physicians consulted with Select Healthcare Solutions, a provider of turn-key medical technology solutions to independent physician groups, to integrate SCINTIX therapy into its comprehensive range of cancer treatment options.
SCINTIX therapy uses signals emitted from a patient’s cancer cells to direct radiation treatment. Patients receive an injection of a small amount of a unique molecule, called a PET tracer, which the cancer cells consume. The X1 detects the signals produced in real time and uses those to determine where to deliver the radiation dose. In contrast, conventional radiotherapy uses static images of anatomy to guide treatment delivery.
About Beverly Hills Cancer Center
Beverly Hills Cancer Center provides a unique model of exceptional care, integrating advanced clinical trials, cutting-edge diagnostics, and innovative treatments. With highly skilled physicians, a dedicated staff, and a tranquil healing environment, BHCC is recognized as a leading private cancer diagnostic and treatment facility in Southern California and beyond. Learn more at www.BHCancerCenter.com.
About RefleXion Medical
RefleXion Medical develops and commercializes SCINTIX biology-guided radiotherapy, a groundbreaking treatment that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to single or multiple tumors. SCINTIX therapy is indicated for use in FDG-guided treatment of lung and bone tumors and is being studied for broader indications. In addition, the company offers the RefleXion® X1 system for conventional radiotherapy for all solid tumors. Learn more at https://reflexion.com/.
Contacts
Media Contacts:
RefleXion
Amy Cook
acook@reflexion.com
Beverly Hills Cancer Center
Sharon Neman
SN@BHCancerCenter.com
Related News
BrightHeart unveils breakthrough AI results at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting, revolutionizing prenatal care
Amid the buzz at JP Morgan conference, Sofinnova Partners' Antoine Papiernik is optimistic
Mainstay Medical announces positive outcomes from landmark RESTORE clinical trial of ReActiv8®
Bioptimus hits $76M funding milestone and prepares to launch groundbreaking foundation model for biology
Mediar Therapeutics enters into global licensing agreement with Lilly to advance first-in-class WISP1 antibody for the treatment of idiopathic pulmonary fibrosis (IPF)